stoxline Quote Chart Rank Option Currency Glossary
  
Addex Therapeutics Ltd (ADXN)
6.7313  -0.689 (-9.28%)    02-11 16:00
Open: 7.41
High: 7.57
Volume: 11,113
  
Pre. Close: 7.42
Low: 6.7313
Market Cap: 11(M)
Technical analysis
2025-02-11 4:43:02 PM
Short term     
Mid term     
Targets 6-month :  9.44 1-year :  10.43
Resists First :  8.09 Second :  8.93
Pivot price 7.68
Supports First :  6.73 Second :  5.6
MAs MA(5) :  7.45 MA(20) :  7.69
MA(100) :  8.8 MA(250) :  9.9
MACD MACD :  -0.2 Signal :  -0.1
%K %D K(14,3) :  25.2 D(3) :  37.8
RSI RSI(14): 38.8
52-week High :  27.89 Low :  6.73
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ADXN ] has closed below the lower bollinger band by 5.1%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ ADXN ] is to continue within current trading range. Bollinger Bands are 12.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 7.58 - 7.64 7.64 - 7.68
Low: 6.61 - 6.68 6.68 - 6.72
Close: 6.65 - 6.75 6.75 - 6.81
Company Description

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot–Marie–Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

Headline News

Tue, 11 Feb 2025
(ADXN) Trading Report - Stock Traders Daily

Thu, 09 Jan 2025
How To Trade (ADXN) - Stock Traders Daily

Wed, 27 Nov 2024
Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year? - Yahoo Finance

Mon, 30 Sep 2024
Addex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results and Provides Corporate Update - GlobeNewswire

Tue, 27 Aug 2024
Crude Oil Dips; Addex Therapeutics Shares Spike Higher - Benzinga

Fri, 19 Apr 2024
Addex to Present at the Swiss Biotech Day 2024 - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 1 (M)
Shares Float 34 (M)
Held by Insiders 0 (%)
Held by Institutions 0.1 (%)
Shares Short 3 (K)
Shares Short P.Month 10 (K)
Stock Financials
EPS -21.19
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 500.1 %
Operating Margin -780.2 %
Return on Assets (ttm) -61.8 %
Return on Equity (ttm) -126.3 %
Qtrly Rev. Growth -81.9 %
Gross Profit (p.s.) -5.72
Sales Per Share 0.8
EBITDA (p.s.) -10.35
Qtrly Earnings Growth 0 %
Operating Cash Flow -8 (M)
Levered Free Cash Flow -6 (M)
Stock Valuations
PE Ratio -0.32
PEG Ratio 0
Price to Book value 673.13
Price to Sales 8.34
Price to Cash Flow -0.92
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android